Floatz logo

AKLAVINE

Acute Myeloid Leukemia

Chinese PLA General HospitalSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
59/ 100

Competitive context

373 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Daunorubicin
Shen yang
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Azacitidine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 4BB
Decitabine
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

AKLAVINE is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
Elderly PatientsDormant
CCC
Indicative ·
53 / 100
View asset →
First Line TherapyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →